Professional Biography
Ogechi N. Ikediobi Pharm.D., Ph.D. is an assistant professor of clinical pharmacy who studies the clinical application of pharmacogenomics. Her research focuses on applying pharmacogenomic knowledge to improve treatment outcomes of chronic diseases such as Cancer and HIV/AIDS. Dr. Ikediobi works in collaboration with geneticists, sociologists, geneticists, sociologists, anthropologists and clinicians in the U.S. and South Africa to evaluate a novel method of measuring long-term exposure to antiretrovirals coupled with the clinical
application of pharmacogenomics to improve antiretroviral treatment outcomes in HIV-positive South African women.

Dr. Ikediobi is trained as both a clinical pharmacist and a geneticist and is committed to
translating basic research findings in pharmacogenomics into clinically useful outcomes.
Dr. Ikediobi received her Ph.D. from the joint National Institutes of Health and University of Cambridge International Biomedical Research Alliance Program in the Health Sciences and received her Pharm.D. from Florida A&M University. Dr. Ikediobi is currently an assistant professor of clinical pharmacy at the University of California, San Francisco where she teaches pharmacogenetics to professional pharmacy students, consults on and interprets clinical pharmacogenetic tests at the Helen Diller Family Comprehensive Cancer Center and the San Francisco General Hospital.

Selected Peer-reviewed Publications

• Shaik MS, Haynes A, McSween J, Ikediobi O, Kanikkannan N, Singh M. Inhalation delivery of anticancer agents via HFA-based metered dose inhaler using methotrexate as a model drug. J Aerosol Med. 2002 Fall;15(3):261-70.
• Ikediobi ON. Characterization of Cancer Gene Mutations in Human Cancer Cell lines for Correlation with Drug Activity. University of Cambridge. (2007). Doctoral thesis.
• Ikediobi ON, Shin J, Nussbaum RL, Phillips KA, TRANSPERS group. Addressing the challenges of the clinical application of pharmacogenetic testing. Clin Pharmacol Ther, Jul 2009 (In Press).
• Ikediobi ON. Personalized medicine: Are we there yet? Pharmacogenomics J. 2009 Apr;9(2):85.
• Lorenzi PL, Ryan MC, Ikediobi ON and Weinstein JN. ASNS (asparagines synthetase). Atlas Genet Cytogenet Oncol Haematol. November 2008; http://atlasgeneticsoncology.org/genes/ASNSID44323ch7q21.html
• Ikediobi ON, Davies H, Bignell G et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther. 2006 Nov;5(11):2606-12. Epub 2006 Nov 6.
• Ikediobi ON. Targeted therapies for the treatment of cancer. California Pharmacist. Jan 2009.
• Ikediobi ON, Reimers M, Durinck S, et al. In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation. Mol Cancer Ther. 2008 Jun;7(6):1337-46.
• Ikediobi ON. Somatic Pharmacogenomics in Cancer. Pharmacogenomics J. 2008 Oct;8(5):305-14.
• Shaik MS, Ikediobi O, Turnage VD, McSween J, Kanikkannan N, Singh M. Long-circulating monensin nanoparticles for the potentiation of immunotoxin and anticancer drugs. J Pharm Pharmacol. 2001 May;53(5):617-27.